they would send a message that crime does not pay basically you lock up really just like one big pharma c.e.o. there will be less animal rape. that's what i'm sayin i think there's a billboard saying that's ill really. but honestly this just in we have to go to my brag but. i am coming your way and you can of come eventually take you to something else faster attack a cork icon couric a. new york a good outcome. for men are sitting in a car when the fix gets shot in the head. for a different version of what happened one of them is on the death row there's no way he could have done it there's no possible way. because they do not shoot around a corner. in july twenty seventh team hunted also to a freelance journalist working with the two militant shelling in syria. so on a second focus the home team has established a holiday also to have a memorial they will recognize war reporters who often risked their lives with the sake of the truth and through that peace you can submit to your published works in a video or britain form go to a little note on t.v. dot com into now. most definitely wasn

lilly or any pharma company when their cash flow is the life blood of the all right i know but either we take their cash or the obstructionist does continue our bake sales of laxative treats like diarrhea i was in lax cooking the. back. i've even brought you some. yes. but no one is buying me it's all right hey you'd be surprised how well lax cookies sell at high school across games when you lie about the ingredients. we get paid and increase their odds of being on sports center. just this not in a way they intended. i know you've got more to talk about but i got to go see that yes that. was even though i same rachel maddow are in the show by forcing you to watch or speak we are not done with them as n.b.c. they're becoming more and more right wing every single day for more on this let's go to redacted correspondent i only care bonnie. and the. n.b.c. the self-proclaimed liberal channel is moving to the rest know hosts are not wielding tiki torches and getting confederate flag tattoos it's worse than that work continues to hire a gaggle of conservative and republican talent simply bec

sanders has put forward a bill that would send opioid exacts to jail the bill would threaten big pharma executives with that least ten years in prison should their companies be found guilty of contributing. to how i write. if you look at market marketing practices and it's about time we lock those mothers early. what was locking them up would send a message to all the other criminals out there like you know bank robbers neck grow feel. the be steal files out there they would send a message that crime does not pay basically you you lock up really just like one big pharma c.e.o. there will be less animal rape because that's what i'm sayin i think there's a billboard saying that they're really. good but honestly this just in we have to go to right bragg much as i am contrary and you can of comedy special tickets are selling out past the redacted tour guide for take how to do was ask you how come the right. to lose the city of luxury and fame but also an alarming number of people living in the street. the simple fact is now ladies there's just not enough shelter even if people on the street

with health care costs guy rocketing and big pharma licking its chops three u.s. senators are backing the trend and putting pressure on one pharmaceutical company after the price on its cancer drug was raised fourteen fold and los angeles r.t. correspondent joshua sweet has more. the cancer drug lomas seen designed to treat brain tumors and hodgkin's lymphoma is nearly a gram per pill so now three senators are probing the pharmaceutical company hoping to better understand the factors behind the rising cost of the drug was first approved by the federal drug administration in one thousand nine hundred seventy six bristol myers squibb sold the company to next source in two thousand and thirteen and since it's been sold the prices have skyrocketed in two thousand and thirteen after the company was acquired by next source the drug was raised to seven hundred sixty eight dollars per capsule then in february the price was raised again this time twenty percent to nine hundred twenty two dollars a capsule but the cost of the highest dose before the company was sold to next

how the direction it headed towards the end of the year now there is that the makers of farm a big pharma companies are playing a blame game with the middlemen and the pharmacies basically saying what this is where is this money going who's making what and why are these a core these are simple the savings that are supposed to be happening getting to the consumers and that all falls into one big snowball that when consumers see they not getting savings this just adds to what's already happening to the pharma industry and that's a lot of bad press with bad press of course people step back from farm as much as they possibly can so people are looking at alternative medicines and we know that there's a big player that came into the market it's happening massively here in canada which is cannabis so when you look at cannabis a lot of people are turning to canada cannabis now instead of what used to be produced by pharma companies be it for an antidepressant be a pain relief be it for hunger management or to actually increase hunger in people like cancer patients so this is all playing again a p

sense of how the direction it headed towards the end of the year now there is that the makers of pharma the big pharma companies are playing a blame game with the middlemen and the pharmacies basically saying well this is where is this money going who is making what and why are these a quarter of these supposed savings that are supposed to be happening getting to the consumers and that all falls into one big snowball that when consumers see they're not getting savings this just adds to what's already happening to the pharma industry and that's a lot of bad press with bad press of course people step back from farm as much as they possibly can so people are looking at alternative medicines and we know that there's a big player that came into the market it's happening massively here in canada which is cannabis so when you look at cannabis a lot of people are turning to canada cannabis now instead of what used to be produced by pharma companies be it for an antidepressant be it for pain relief be it for hunger management or to actually increase hunger in people like cancer patients so this

cannabis a lot of people are turning to camp cannabis now instead of what used to be produced by pharma companies be it for an antidepressant be a pain relief be it for hunger management or to actually increase hunger in people like cancer patients so this is all playing again a part of this game here and of course in the states one big factor has been the opioid crisis which has left a bad taste in a lot of people's mouths in our country and your country absolutely well we're going to have you back to talk more about that about the price of drugs too as we go forward thank you very much arctic correspondent alex mahela bitch. and thank you all for watching be sure to catch boom bust on youtube youtube dot com slash boom bust r t we'll see you again. thank you. thank you you thank . you never know what's around the corner you never know what's in the pub you going to walk into that excitement is that not knowing that's where the adrenaline in much comes from. and you can easily move by definition and the extremes will support. the violence he's a part of and it's almost a schizophrenia.

we talked about how the pharma sector is associated with this.talk about the dynamics, credit, a lot of dry powder in the private equity space. has it been such a good year for m&a so far this year? has it been the start people were anticipating? kristine: there has been a lot of interesting deals and it focused on certain sectors that arguably could use some modernizing and consolidation in terms of deficiencies. that would be a positive. mentioned, as you there are other factors like the availability of credit, especially at a time where investors seem to be souring on credit markets. that could be something that would hurt primary issuance given the demand of this space might be pulling back a little bit. matt: when you step back and look at equities, are you bullish or bearish for this year? taking aouse, we are more encino syncretic -- idiosyncratic stance, rather than being a longer beater of the market. you should look at some of the volatility you have seen in equity markets recently. data,ope, you had weaker in the u.s. you had tighter f

that will hit the pharma sector. than 5%.ticals of more industrial tools and materials as well. we are seeing a rise of 2%. usually the one that has been under the most pressure, acc, one of the ones hardest hit. we are seeing that down about 1%. defense also one sector to watch out for. that is rallying today. responsebeen a muted from investors so far. we are waiting for clarity on the china response as well. tothe meantime let's get first word news with paul allen in sydney. >> thanks, yvonne. get ninesurance will $.7 billion to ensure policy and maintain stable operations. regulator approved the capital injection on march 28. founder prosecuting the and chairman for fraud and embezzlement. market has achieved valuation, $27 billion, after trading on the new york stock exchange for the first time. shares closed 10% below the opening reference price. 1/6 of its almost 10% stake. agencyld's biggest ad imposing an independent counsel to research personal misconduct against sorrell. wpp says allegations do not involve anything material to the agency. theays he rejects allegations

big pharma is in big focus ifi pfizer and merck report their earnings tomorrow morning.ter than meg to help us with those numbers >> we'll start with merck. the big thing is cetruda it's a huge immunotherapy drug they had research and people will wonder how that momentum going to coin. people are also wondering, what is next in the pipeline? what else is going to contribute to growth? people will listen closely to that an for pfizer, the main thing is m&a, lots of speculation about whether pfizer will do a big deal they had those huge transactions they attempted in recent years neerbt of which transpired there's been a lot of speculation whether they might go for bristol myers although the management team had been talking it down. and we'll mention allergan today. the sock is down, even though the quarter was beat top and bottom line and they raised guidance hearing that, even though they outlined ideas for strategic evaluation of the company, jus some confusion among investors on what is happening there interesting to see the stock down 4% on a good quarter. >> coming i

pharma had another strong quarter.as some concern at the end of first just of the first quarter that pharma might slow continuesthe business to perform very well at 50% growth in the first quarter, and we are confident it will -- 15% growth in the first quarter. david: what about remicade? that has been a big driver that is tapering off. what is the rate of decline? dominic: in the quarter, about 22%, a little bit of an unusual decline because of rebate adjustments. about 15% decline as we expected, that even with that decline, the pharma business had strong, above market growth, and we think it will continue despite remicade's klein. -- climb. david: as remicade climbs, what will take its place? dominic: a number of very important oncology drugs. productsot new approved, and we still plan to file eight additional new medications, each having more than $1 billion in sales by 2021. david: tell us about the launch of the janssen product that deals with psoriasis. dominic: it launched recently, it is a new mechanism of ac

it put the unit up for sale last year to focus on the pharma business, particularly prescription drugs procter is due to release its quarterly results later today. feel free to e-mail the show about some of these numbers. the address is streetsignseurope@cnbc.com you can follow us on twitte twitter, @streetsignscnbc or tweet me directly. >>> coming up on the show, the international monetary fund warns global debt is higher than before the financial crisis. stay with us racing isn't the only and with godaddy, i'm making my ideas real. with godaddy you can get a website to sell online. and it will look good. i made my own way. now it's time to make yours. ♪ everything is working just like it should ♪ you know what's not awesome? gig-speed internet. when only certain people can get it. let's fix that. let's give this guy gig- really? and these kids, and these guys, him, ah. oh hello. that lady, these houses! yes, yes and yes. and don't forget about them. uh huh, sure. still yes! xfinity delivers gig speed to more homes than anyone. now you can get it, too. welcome to the party. >>> the im

washington to keep cannabis scheduled as a drug that should not be allowed to be legalized it's big pharmabig alcohol, although look at constellation brands who did a big deal with canopy and ultimately this is telling you a lot of these guys are actually not playing defense but offense in this sector so you are seeing substitution effects. here is what i want to talk about breakdown of indexes people are very aware what's going on in recreational i get it we know what's going on there. for a lot of people recreational is a much more complex market, much more global market, it's really a substitution effect medical we know what's going on there. on the wellness side, i can tell you that's the path everybody draws from goes from these three, leading to lifestyle brands. let's get to some of the names these are big players. we want to give you names big market caps well-known companies executing every single day we talked about canopy, they would be the big recreational play ultimately this the company really out there they set the biggest market cap, land grab, pharma, mel talked about them

these scientists at neuro pharma put neurons, those brain cells, in two petri dishes. one on the right, they fed the same neuropeptides that are in cebria. and the one on the left, they did not. the neurons on the left are alive, but they're not really thriving. they're just there. now look at the neurons on the right. they are thriving. they're robust. you can actually see the new branches growing, reaching out, making new connections. this is really revolutionary. this is nature right there telling you the truth. not hype, real science. in fact, dr. thomas crook, a former taskforce chairman at the national institutes of mental health said, and i quote: and he's just one of the growing community of renowned doctors and researchers who recognize the remarkable effect of cebria. this is the very first product that contains what we call neurotrophic factors or growth factors. and these growth factors actually helps the neurons grow. what we have been able to show is a significant improvement in a placebo-controlled study, a significant improvement in memory tests. cebria

we spoke with the ceo of gw pharma right after the panel vote today. concerns about potential misuse. >> a good body of today's meeting was, in fact, focused on what is term abuse potential of cbd and it was clear, both from our studies and from the fda's review that the abuse potential was deemed to be low. >> still, because of dea skenging, there would be about a three month delay after approval if it get approved for when the drug becomes available the side effect, the panel focused on liver safety something that may require monitoring as for the medicine's financial prospect u.s. revenue at more than billion dollars. gw stock closed flat it does follow a jump earlier in the week. mel, there's a lot of excitement among the patient who are waiting for this drug, severe epilepsy is a terrible condition. >> meg, thank you. >>> tim, you actually own gw pharma. >> this is such a big day. what the ceo is also talking about the process for approval and the process for all the clinical trials is a very riggerus scientific process and this is part of the vic

chinese pharma stocks are slipping. softbank shares in focus.ts sprint and t-mobile have talk for a deal. david: thank you so much. let's dividend have a look what sophie was mentioning, trade tariff tensions. when you look at markets and how we traded over the last 48 hours, there seems to be a cease-fire priced in. we talked about a looming trade war or trade tensions a couple days back. maybe not. president trump welcoming president xi's discussion to open the economy. it may be a temporary lull. our bloomberg gadfly columnist , david, to talk about why there is less change than meets the eye here. david: that is right. it is fairly clear when you go through the four key points from xi jinping's speech at the boao forum yesterday. up autos about freeing and the financial sector, those have been under consideration more than a year. nearly five years at this stage. the sectorsducing where investment is restricted, that is an ongoing discussion, has been for 23 years. thirdly, ip protections, has a if of people excited, but you look back to spe

deal flurry in pharma.tentially considering an offer for shire in a bidding war with takeda. joining us now in london is bloomberg steel reporter -- bloombergs deal reporter -- bloomberg's deal reporter. joining us in new york is the editor of business week. bring us up-to-date with where allergan is. suddenly it is back again, making this huge offer or so we believe. >> allergan have been tending to its own for a while after making a series of deals and then over the last six months or so, we have seen them under some pressure from investors. people thinking they might have to selloffs of assets or do something to get their business under control. all of a sudden they are interested in what could be a $60 billion plus deal. it seems like they may be looking at a way out of this situation as doing another big deal and snap up big potential assets. vonnie: fascinating. the size of the offer is massive. can they carry that on their balance sheet? i think both of the bidders -- keep in mind takeda is coming in

the egyptian pharma is the one who your innate supply and. i was going with the lesson was that we know what we shall keep them. my great grandfather had bosh and his son of sardaar we had both died of bilharzia on that day in parliament the minister of interior noted down my name on a sheet of paper in front of him. dr no while el saadawi the medical doctor in charge of the health unit of coffee tulla has exhibited a signal disrespect for the moral values and customs of our society and incited women to rebel against the divine laws of his law. this became the accusation that was leveled against me it followed me wherever i went step by step move through the corridors of government administrations year after year irrespective of who came to power. until the present day. even so i get seizures they knock me out for a half hour or longer i'll tell you what i am selling if you've been having these seizures how long a long time i think i already had them when i was young at least for as long as i can remember. them or you were married yes then th

justice department will give the green light to german pharma giant by its takeover of monsanto that just a few weeks off to the potential deal was given the ok by the e.u. commission of course intending to buy the u.s. agricultural colossus for sixty two billion dollars u.s. officials have insisted divest additional assets as part of the deal it will now go smoothly they make a deal will be the biggest have a takeover of a u.s. company by a german one. and we can bring in our financial correspondent daniel cope who's following the story for us from the frankfurt stock exchange daniel that final green light from across the atlantic appearing to seal the deal how are investors taking that piece of news in fact very positive had another merger has been taking a longer than expected and even though some investors still fear that this merger the biggest by the way in german history even for a company like buyer could be too big too risky already last night on wall street during the after our trading shares of buyout jumped higher plans of two point one percent want some top shares jumped

chairs of gw pharma are down now but they have been up.a first on cnbc interview is next. to buy or sell?t be tie with fidelity's real-time analytics, you'll get clear, actionable alerts about potential investment opportunities in real time. fidelity. open an account today. welcome to holiday inn! thank you! ♪ ♪ wait, i have something for you! every stay is a special stay at holiday inn. save up to 15% when you book early at hollidayinn.com >>> hello, everybody, i'm sue he are rera the justice department has just received a referral from its inspector general's office recommending it bring charges, criminal charges, against former fbi deputy director andrew mccabe however, that referral does not necessarily mean that charges will definitely be filed >>> "time" magazine is out with its annual 100 most influential people, and making this list this year is houston texans defensive end jj watt. last year, he donated $100,000 of his own money to hurricane harvey relief efforts and he helped raise an additional $37 million. >>> a connecticut sup

a pharma player jumping.laggards in tokyo animation stocks, those are sinking. some others tracking declines in samsung. and what we saw overnight in players like macron. takeda sinking. he said they might buy all of shire, worth as much as $50 billion, rish. rishaad: renewed fears of a trade war giving u.s. stocks a boost. waiting perhaps for the storm to blow over. bond bears are willing to see if the friday peril numbers give them the green light to push yields higher. kathleen has a jobs preview. it is all about wages again, isn't it? once again in focus on the backdrop of this escalation in the trade battle. not a call to war yet. you kind of wonder how much difference it will make. we know that 8:30 eastern, wall street time on friday, every to their screen, their bloomberg, to see what these numbers do. here is what will make it more difficult. march on the east coast was very wintry. this could definitely cloud at the jobs report. let me explain how. first of all, this harsh winter weather could have

that cash back it will be shopping season >> if anything some of these pharma ceos have been called's good to do a deal because you buy the growth, "b," distract your board for a couple mo months or quarters >> when you raise the sifi limit, things grow what do you mean by that >> above a certain level of size if you're a bank you had the government move in as your partner and regulator. >> we're from the government, we're here to help >> exactly >> that mimt mlimit may be rais. companies that didn't want to grow, they may want to grow now. >> so some change in bank regulations may help the deals we've already seen fund managers talk about this. we have strong economic growth, m&a and trade. this is interesting. innovation is a top five reason for small caps no offense to any small cap company watching now if you're a ceo, i don't think of innovation when it comes to small caps. they don't have the r & d budgets. >> we talked about this a lot. we think we're in an industrial revolution in particular software you want new software solutions. some of the big f.a.n.g. companies will ha

lisa, the thing is there has been a big urge to merge in the pharma space. doing it?have their own specific reasons compared to others who have been merging with the different ones? this attempt to buy shire is one of the steps that takeda has taken to become a global farmer powerhouse -- pharma powerhouse. the ceo chris webber is the first foreign ceo the company has had. it is a 200-year-old company. itss facing challenges with late stage clinical drug pipeline. there are a few candidates. company isy, the facing pricing pressures on its drugs in the domestic market. buying shire will give it access to a portfolio of diseases, as well as a footprint in the united states. if the deal does happen, takeda would become one of the top 10 global farmer companies by sales as well. rishaad: thank you so much for that. bloomberg news asia consumer reporter. coming up, global carmakers rolling into china trying to woo the world's biggest auto market. that is next. this is bloomberg. ♪ rishaad: you are back with bloomberg markets. let's get to the beijing auto show. our next g

gw pharma, they have a lot going on >> dan >> yeah, so i think there is politics in this sector.ler >> what is particularly salty tonight. flo, i can tell. >> he is the same salty, same salt as every other night. >> he has a purple tie on which is very inviting and friendly. >> goldman sachs initiated free port in march with a $23 price target >> take it, pete >> giddyap. >> $19 and change. i' >>> my mission is simple, to make you money i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now >>> hey, i'm cramer. welcome to "mad money. welcome to cramerica other people want to make friends. i'm just trying to save you some money. my job is not just to entertain but to educate and teach you so call me at 1-800-743-cnbc or tweet me @jimcramer. >> what's a sure fire way to send your stock higher even at

one of our own value investors is on the hunt, and it's in the pharma sector today. firestone is chairman and ceo of res asset management, joins us from boston good to see you again. >> hey, scott, great to see you. and congratulations on your upcoming book launch >> thank you so much i was looking at the stock, you're adding to a stock, right? not a new purchase, but it's a bold one, nonetheless, because bristol myers has laid an egg, and i mean big time. you could pick almost any metric you want between 1, 3, 5, or a year >> well, bristol has been a tough stock, and we bought it the last time it really cracked. we bought it around this level, a little lower than this level originally now that they had a clinical trial on lung cancer with a drug that has worked, worked very, very well, and it's been great in melanoma. it showed results in lung cancer that met the primary end point, but they weren't as good as cetruda, and that's really the problem, that it showed fantastic results. merck's were good, not as good as expected. i think there were lots of hedge funds ar

ider pharma >> we are seeing this movement into the gene therapy space.g in been this for a wild. i think we will see more. it is an area where you are basically using technology to alter dna of a patient, and an might be able to cure incurable disease. there are so many experimental companies out there. the company being bought now has the first drug coming to the market, still experimental. there's a lot of opportunity, but also a lot of downside risk. if things don't work out, you have to write off the investment. but to pull the company's out, very large. more companies are moving into the field and novartis is making a first and bold effort here. manus: $9 billion deal in context, and the scale of the global economy. thank you very much for summing up the deal. we have had quite a bit of an and a activity as of late. are you going to come out with the late cycle activity management, i think i have seen more? good deal for novartis. a good shakeup in pharma. >> i think overall the environment has been conducive m and a. a -- profitability of the corpo

pharma there are a lot of political robo calls. and charitableobo calls are all legal to land line telephones. the reason we're getting so many, the technology makes it so easy for the bad guys to use these ings, the scammers or companies that aren't following the rules.es big compa recently have been fined for this, and they work. people respond to eythem. et a call that says it's the irs calling, you owe us money. and they pay the money when the irs doesne telephone calls. yeah, we have to get a lot arter and not fall for these things. >> what is the irs trying to do about all of this?>> e can block the calls, but why can't they stop the calls from coming? >> we can't even block the calls in every case. just today, a bill was introduced in congress, called the robo cop act which would try to help the situation. the phone company started out by saying they couldn't block these calls at all. the ftc said yes, you can. they fought doing it, and now their technology to do it, i have a service cl nomorobo. it blocks all the robo calls

we do not take money from the pharmaceutical companies, big pharma, alcohol or cigarettes and we are funded by individuals who have suffering heart ache from addiction. i want to turn it over here. we have a very prestigious group of folks here and i'm going to turn it over to jake nelson, the director at aaa. to talk about impaired driving. we have a warning for impaired driving. jake. >> i knew that was going to happen. [ laughter ] >> soon as we crowded. good afternoon, everyone. in 2016, 10,497 people died from drunk driving. the rates have dropped over 30% in the last decade. the same period of time, the rates of marijuana use increased 50%. this is a drug that we know without hesitation at least doubles crash risk. it does it by impairing drive attention, coordination and reaction time among other skills important for safe driving. mixing alcohol with marijuana -- this is the most common way that people who use marijuana and get behind a wheel of a car use it. they mix it with alcohol, almost two-thirds of a time. data suggests that legalizing marijuana for fun or recreational

. >> reporter: allergy medicines are big business for the pharma industry, drawing more than$2.6 billion in u.s. revenue in the last year accord to data. that's just for over the counter products like j &j zyrtec. and doesn't include prescriptioe cines. the costs for consumers can add up. sandra uses a prescription inhaler that she says costs her $50 out of pocket. >> there are pple t cannot get relief because they can't pay the price. her andter: but for other allergy sufferers like this 26-year-old student and waitss jessica, going without illery medicines is not an ustion. >> i'm going to be like waterfall of just all over the ple i guess. it's, yes, it's an uncomfortable feeling. >> reporte here's wishing everyone a less sniffly spring. for "nightly business report," from the new york botanical garden, bronx, new rk. >>> coming up, the new ways to get to space.>> i'm morgan brennan in colorado springs. it is the biggest space conference of the yeand one of the hottest topics, blue or jens rocket engines. we catch up with the spa company created by jeff bezos tk bout space tourism, it

joined my colleague andrew pharma in the studio to discuss the latest. almost in the past few years that we've seen the scandal and revelation say it has been established that pretty much every single athlete in russia dops or it seems it was common knowledge at least that they had a special drug cocktail brewed performance that the swapped the dirty urine samples for clean ones through some hole in a lab wall so a lot of was said and was said by a man named grigori roche and of so he was the key witness he put forward the allegations but in the in the case basically during that hearing the court of arbitration for sports he revealed that many of the stuff that he said was best circumstantial first and foremost he said that he never actually administered the said cocktail which he claims he concocted himself he says that he never saw anyone administering these said steroid cocktail he didn't know how the cocktail was smuggled from russia abroad because well you know to be used in an international championship it would have to cross the border and also he

big pharma so this is great news for us certainly you know let's throw some more drugs at these kids rather than actually try to help them cope and for the necessary you know tools they need to get over like this kind of p.t.s.d. you know when we comes to gun violence the one thing we really have to understand is that according to the centers for disease control and prevention you have twenty seven hundred children and teens ages zero to nineteen are shot and killed and over fourteen thousand marshall. injured every year so that's an average of forty seven american children and teens shot every day either through accidents or bad so we do have to think of the kids that we do all right everybody as we go to break hard watchers don't forget to let us know what you think of the topics we've covered a facebook and twitter seo poll shows that are coming up we'll bring you the second half of those delve into the files of the j.f.k. assassination with researchers author jim but the huge ego state to. twenty eighteen coverage we've signed one of the great just kill people. but there was one

that the story lives and families this is a very strong argument for heavily taxing the profits of pharma companies investors and other one percenters and then turning the money over to publicly funded scientific research that assumes all patents i like where that's go a good set up the good stuff there. it is it's cost effective you should be. right as we go to the word as we corporate court watchers were good to let us know what you think of the topics we've covered facebook and twitter still poll shows that are t.v. dot com coming up shawn stole the soldier this is richard james the eugene o'neill to discover what to do great. any company is still in the. process of just kind of stay true to the. law. you never know what's around the corner you never know what's in the pub even to walk into excitement it's that not knowing that's where the adrenaline in much comes from. and you can easily move by definition and the extremes will support. the violence is a part and it's almost a schizophrenia gang culture where you can do all these things and behave like badly. important people of cours

mr lund will remain as chairman of danish pharma firm, novo nordisk, when he takes up the bp role nextits us sedan car models to focus on suvs and pick—ups. the auto giant says it will now cut $25.5 billion in costs by 2022, up from the $14 billion it announced last autumn. chief executive jim hackett told investors the company is undergoing "a profound refocus" of its operations. nintendo's profits rose for the year to march, beating its own forecasts after it was repeatedly raised its annual targets. let's go to beijing now, where global car—makers are gathered for the annual auto show. robin brant is there for us now. interesting timing giving the spat between the us and china as far as ta riffs between the us and china as far as tariffs and a trade war is concerned. is that overshadowing events there? i wouldn't say overshadowing body bits on the mind of senior executives we have been speaking to. —— but it is on the mind. events like this have a big draw. we have been speaking with bmw. their chief executive. also the ford senior man for the asia—pacific region. the prospect of a

but below the scene if you think about just pain relief and sleep disorders, and this is 80% of the pharma in this country, this is why the entire cbd space is so fascinating and why really it's nice to rerun "fast times at ridgemont high" but the bottom line is this is a real story, these are real considerations and there's real brands being built within this space, brands matter, and they'll hold on to their margin even if the product prices go down. >> weed week is over, but coming up brian kelly has a bitcoin chart so crazy you might actually think you are high. it's got major implications for the market and he will explain i'm melissa lee, you're watching "fast money" on cnbc in the meantime here's what else is coming up on "fast. >>> oil is surging and it's taking energy stocks with it but the chart master says he sees something in the charts that could be signaling the party is over. he'll tell us what that is >>> plus, shares of boeing have been looking a lot like its planes, flying high. but one trader thinks the stock is about to get ouedgrnd he'll explain why when "fast money" r

justice department will give the green light to german pharma giant buyers take over all of monsanto that just a few weeks off the potential deal was given the ok by the e.u. commission by tends to buy the u.s. agricultural colossus for sixty two billion dollars u.s. officials have insisted that by divest additional assets as part of the deal before now goes smoothly the mega deal will be the biggest ever take over all of a u.s. company by a german one. back over to daniel in frankfurt daniel so this merger appears to finally have the green light all round despite so many concerns. yeah exactly it seems that the merger is finally now a done deal we're still waiting though for the official confirmation and yes there have been many concerns mostly many feel that by i will from now on some even say an absolute monopoly in this area so until the very end it was not clear if the merger. would get the approval from the u.s. and also e.u. authorities this was very frustrating also for shareholders because of all this issue the merger has been taking much longer than origin lee planned also

that the story lies in families this is a very strong argument for heavily taxing the profits of pharma companies investors and other one percenters and then turning the money over to publicly funded scientific research that assumes all patents i like where that's go a good set up the good stuff. makes my heart hurts lester's it is it's cost effective you should get it at the. right as we're going to bring it to the national it's as big corporate car quadrupled we're going to let us know what you think of the topics recovered on facebook and twitter still poll shows that r t v dot com coming up shawn still says that with your predecessors richard james the u.g.a. wanted to discover what do breaks if any of come of the historically this issue of that was part of the job of kind of stay true to what. they claim is a black hole and it is sucking folks from all walks of life and money from all points on the globe and as it expands it's just a war of the size of anything else trying to keep with it that includes various beyond money regimes that also includes very high level bankers and econ

if everybody is now looking at pharma saying, they got us into this mess because they had unscrupulous practices of selling more oxycontin than were needed because they were making bigger profits, the more people they got hooked, higher those profits would be, why would we be at this stage of our lives as a nation, well, let's repeat that mistake? instead of oxys, we'll have owl these new forms of this new addictive drug, thc, because it is not marijuana. it is elixirs. i don't know if everyone heard what elixir, like fanta orange ade with thc in it. you have at the bar, you have red bull and now you see where i'm coming from. you have elixir, you have now another chemical to bring to the table. and of course, they're edibles. what the hell are edibles people tell me? those are the things that you might not be aware of how much thc in what you're eating. hence all the emergency room visits, people thought, well i only took a bite or two. never made any impact on me. i finished the brownie. next thing i knew i was hallucinating in in an e.r. let's not just look this in anecdotal in term

that's what we do not take any money from the pharmaceutical companies or big pharma, opioid manufacture, alcohol or cigarettes and we're funded by individuals have had really suffered heartache from addiction. i want to turn it over. we have a very, very prestigious group of folks here and i'm going to first turn it over to jake nelson, the director of traffic safety and efficacy research at aaa to really talk about this issue of impaired driving. because on this unofficial mayor one holiday we have warning for those on the roads, given this issue of impaired driving. jake. >> i knew -- in 201,610,497 people died in crashes due to drunk drivers. that's in the period of time when the rates of drunk driving had dropped over 30% in the last decade. now this same period of time the rates of marijuana use among drivers has increased almost 50%. this is a drug that we know without hesitation at least doubles crash risk. it does it by impairing driver attention, coordination and reaction time among other skills that are very important for safe driving. now mixing alcohol with marijuana produce

justice department will give the green light to german pharma joined by is takeover of monsanto just a few weeks after the potential deal was given the ok by the e.u. commission by intends to buy the u.s. agricultural colossus for sixty two billion dollars u.s. officials have insisted that by divest additional assets as part of the deal a full now goes smoothly mega deal will be the biggest ever taken all the u.s. company by a german one. back over to daniel in frankfurt daniel the merger appears to finally have the green light despite many concerns. yes exactly where and there are still are lots of concerns because we have to face as with this merger by our monsanto we'll have a mano paly position that is the reason why until the very end approvals from the us and also e.u. authorities were pending and monsanto has said in the past that their version at least with this merger they will play a major role to make sure to meet the rising demand for food in the future others see all of this very different mostly farmers are concerned their fear that their seed cause go up dramatically a

that the story lies and families this is a very strong argument for heavily taxing the profits of pharmacompanies investors and other one percenters and then turning the money over to publicly funded scientific research that assumes all patents i like where that go a good set up there good stuff there makes my heart is yours lester's it is it's got its effect on you so if it is it is very busy right as we go to the international desk as big corporate card watchers go good to let us know what you think of the topics we've covered on facebook and twitter seo poll shows that r.t. dot com coming up shawn still says that with their peers at least richard james the u.g.a. wanted to discover what new breaks if any of the company has stored this sort of. pressure to just kind of stay true to the actual. look at the blockade and the animosity for fifty almost sixty years did it change the regime in cuba no the last administration realized that the majority of cuban americans wanted normalizations the normalised and when you normalize you can talk . and i want to tell you from my experience in cub

it is different from the pharma bro and that was disastrous. >> facebook wants to be regulated.hat we are looking at is markets moving into maturation, the adolescence of this. the big ones don't want the wild west anymore. what happens when a company failed as completely as facebook has competitive market forces would drag them under and they would go down. what they are looking for is the gentle protective custody of the federal government, they spend money on lobbying and do all this pr and suck up to politicians and create a regulatory structure that protect them from competition, there will be new rules to live by a couple billion dollars profit and take this out. shannon: sen. john kennedy, what he is saying about it. >> i'm not interested in regulating -- shannon: i won't regulate them to death. what questions do you think? is the so different than the world he operates in? >> they existed in this -- is thick in washington. and the silicon valley billionaire who is not accustomed to these issues. let's remember whatever congress does is secondary to the national discussio

justice department will give the green light to german pharma giant buyers takeover of monsanto that just a few weeks after the potential deal was given the ok by the e.u. commission by intends to buy the u.s. agricultural giant for sixty two billion dollars u.s. officials have insisted the buyer divest additional assets is part of the deal that if all now goes smoothly the make a deal will be the biggest ever take of all the u.s. company by a german one. and we can bring in our financial correspondent daniel corp who's following the story for us from the frankfurt stock exchange daniel that final green light from across the atlantic appearing to seal the deal how are investors taking that piece of. in fact very positive had another merger has been taking longer than expected and even though some investors still fear the merger the biggest by the way in german history even for a company like buyer could be too big too risky already last night on wall street during the after our trading shares of buyout jumped higher class of two point one percent monsanto shares jumped even higher to